The U.S. Food & Drug Administration (FDA) is now investigating a possible link between Kombiglyze XR and heart failure. The review follows release of a clinical trial which suggested saxagliptin was associated with a 27% increased risk of hospitalization for this potentially life-threatening condition.
You may be eligible to file a Kombiglyze XR lawsuit if you or someone you care about were hospitalized with a heart failure diagnosis while using this medication to treat Type 2 diabetes. To learn if you are eligible to pursue compensation from the manufacturers of Kombiglyze XR, please call (888) 994-5118 to discuss your case with one of our legal experts.
Kombiglyze XR is a DPP4-inhibitor that belongs to a class of Type 2 diabetes treatments called incretin mimetics. The medication consists of both saxagliptin and metformin. Kombiglyze XR is marketed by AstraZeneca, which obtained FDA approval for the drug in November 2010. AstraZeneca also markets Onglyza, a saxagliptin-only diabetes medication that was approved the previous year.
A patient experiences heart failure when the heart is no longer able to efficiently pump oxygenated blood to other parts of the body. As the condition progresses, the muscles of the heart can become thicker, forcing it to pump faster. The heart will grow weaker, and the patient will develop congestive heart failure as fluid builds up in the lungs, liver, gastrointestinal tract, and the arms and legs. There is no cure for heart failure, but there are a number of effective treatments that can relieve symptoms and prolong life.
Heart failure symptoms may include:
The nationwide law firm of Bernstein Liebhard LLP is now offering free, no-obligation legal reviews to individuals who were hospitalized with heart failure diagnosis while using Kombiglyze XR. To learn more, please contact our office by calling (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.